Edoxaban monotherapy superior to dual therapy in patients with high-risk AF and stable CAD
Edoxaban monotherapy reduced net adverse clinical events compared with edoxaban plus a single antiplatelet agent, when used as long-term antithrombotic therapy, in patients with high-risk atrial fibrillation (AF) and stable…